Open an account

Veradigm

MDRX · OTC

$4.75−$0.25 (−5.00%)TodayMarket closed ·
Prev close $5.00

MDRX analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Jul 17, 2024

Bull case

Veradigm is showing strong potential for growth and profitability. Notably, it is making progress in improving its financial health, evidenced by its successful efforts to decrease debt, realign its solution portfolio, and drive revenue through data sharing agreements. The company also has an excess of net cash and a promising business strategy that includes acquisitions, strategic partnerships, and initiatives to expand its margins, providing potential for double-digit revenue growth in the coming years.

Bear case

Veradigm is facing several financial challenges as highlighted by a downward revision of its anticipated revenue for 2023, which is down 1.6% due to lesser new wins and a higher churn rate than expected. Furthermore, a 22.1% drop in EBITDA is projected due to factors such as an organic revenue shortfall and one-time additional personnel expenses. Compounding these financial issues is the threat of a declining customer base like that of the Touchworks agreement as significant clients like Northwell are shifting their allegiance to competitors, which magnify the uncertainties around future growth and market position in the highly competitive healthcare technology space.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.